{'fraction_non_alphanumeric': 0.023529411764705882, 'fraction_numerical': 0.0022058823529411764, 'mean_word_length': 5.737623762376238, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmaceutical Journal of Indonesia

Diabetes mellitus is defined as a group of metabolic disorders caused by multiple aetiologies, characterized by hyperglycaemia with disorder of carbohydrate, protein and fat metabolism resulted from defects in insulin secretion, insulin action, or both. The clinical diagnosis of diabetes might manifest as polyuria, polydipsia, and unexplained weight loss, and confirmed hyperglycaemia. In type 2 diabetes progressive loss of b-cell insulin secretion often causes insulin resistance. Insulin resistance manifestations include increasing lipolysis and free fatty acid production, increasing hepatic glucose production, and decrease in glucose intake into skeletal muscle. Alogliptin is a new class of oral hypoglycemic agents, highly selective DPP-4 inhibitor which has been approved of FDA. Alogliptin can be used as monotherapy or in combination with other anti diabetic agents such as metformin, sulfonylureas (glyburide), pioglitazone, and insulin. Based on several studies, alogliptin shows low risk of the occurrence of side effects, such as hypoglycemia, edema, weight gain, RA, joint pain and cardiovascular events. The purpose of this review is to update clinical information about the effectiveness and side effects of alogliptin as diabetic therapy in T2DM patients. Sinurat et al: Effectiveness And Side Effects